Three medicines treating HIV, pain and cancer have been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) at its latest meeting.
Read More
Gilead’s new combination therapy Biktarvy has been approved by the US Food and Drug Administration for the treatment of HIV.
Read More
European regulators are now reviewing Gilead’s fixed-dose combination of bictegravir (BIC), emtricitabine and tenofovir alafenamide as a treatment for HIV-1 infection.
Read More
Gilead has unveiled data from a batch of late-stage trials showing that its investigational HIV therapy bictegravir was non-inferior to ViiV Healthcare’s flagship drug dolutegravir in suppressing levels of the virus.
Read More
